4 results on '"Jacqueline C. Barrientos"'
Search Results
2. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
- Author
-
Francesco Forconi, Jae H. Park, Martin S. Tallman, Brunangelo Falini, Robert J. Kreitman, James B. Johnston, Sameer A. Parikh, Timothy G. Call, Xavier Troussard, Seema A. Bhat, James S. Blachly, Sasha Dietrich, Gerard Lozanski, Matthew Cross, Jacqueline C. Barrientos, Thorsten Zenz, Claire Dearden, Sunil Iyengar, Alan Saven, Francesco Lauria, Judit Demeter, Gunnar Juliusson, Tadeusz Robak, Douglas E. Gladstone, Versha Banerji, Kerry A. Rogers, Enrico Tiacci, Tamar Tadmor, Pier Luigi Zinzani, John F. Seymour, Farhad Ravandi, Bernhard Wörmann, Constantine S. Tam, Michael R. Grever, Aaron Polliack, Alessandro Gozzetti, Clive S. Zent, Eric H. Kraut, Leslie A. Andritsos, Grever M., Andritsos L., Banerji V., Barrientos J.C., Bhat S., Blachly J.S., Call T., Cross M., Dearden C., Demeter J., Dietrich S., Falini B., Forconi F., Gladstone D.E., Gozzetti A., Iyengar S., Johnston J.B., Juliusson G., Kraut E., Kreitman R.J., Lauria F., Lozanski G., Parikh S.A., Park J., Polliack A., Ravandi F., Robak T., Rogers K.A., Saven A., Seymour J.F., Tadmor T., Tallman M.S., Tam C.S., Tiacci E., Troussard X., Zent C., Zenz T., Zinzani P.L., and Wormann B.
- Subjects
Cancer Research ,medicine.medical_specialty ,Consensus ,Hairy Cell ,medicine.medical_treatment ,Diseases ,Consensu ,Review Article ,Disease ,Severity of Illness Index ,Internal medicine ,medicine ,Leukaemia ,Humans ,Hairy cell leukemia ,Intensive care medicine ,Cladribine ,Pandemics ,Leukemia, Hairy Cell ,Leukemia ,Hematology ,Pandemic ,SARS-CoV-2 ,business.industry ,Standard treatment ,COVID-19 ,Immunosuppression ,Practice Guidelines as Topic ,medicine.disease ,Oncology ,business ,Human ,medicine.drug - Abstract
Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19.
- Published
- 2021
3. Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial
- Author
-
Marco Montillo, Anna Schuh, Miklos Egyed, Franck Morschhauser, Árpád Illés, Tadeusz Robak, Julio Delgado, Andrew D. Zelenetz, Alexander S. Pristupa, Herbert Eradat, Wojciech Jurczak, Sanatan Shreay, Jacqueline C. Barrientos, and Malgorzata Wach
- Subjects
Adult ,Male ,Bendamustine ,medicine.medical_specialty ,Visual analogue scale ,Health-related quality of life ,Kaplan-Meier Estimate ,lcsh:Computer applications to medicine. Medical informatics ,Placebo ,law.invention ,Idelalisib ,Double-Blind Method ,Randomized controlled trial ,Quality of life ,law ,Internal medicine ,Statistical significance ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Bendamustine Hydrochloride ,Humans ,Randomized phase 3 study ,Relapsed/refractory CLL ,Aged ,Quinazolinones ,business.industry ,Research ,Public Health, Environmental and Occupational Health ,Patient-related outcomes ,General Medicine ,Middle Aged ,Leukemia, Lymphocytic, Chronic, B-Cell ,Purines ,Quality of Life ,lcsh:R858-859.7 ,Female ,Rituximab ,business ,medicine.drug - Abstract
Background In a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in adult patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Here we report the results of health-related quality of life (HRQL) analyses from this study. Methods From June 15, 2012 to August 21, 2014, 416 patients with R/R CLL were enrolled; 207 patients were randomized to the idelalisib arm and 209 to the placebo arm. In the 416 patients randomized to receive bendamustine/rituximab and either oral idelalisib 150 mg twice-daily or placebo, HRQL was assessed at baseline and throughout the blinded part of the study using the Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu) and EuroQoL Five-Dimension (EQ-5D) visual analogue scale (VAS) questionnaires. The assessments were performed at scheduled patient visits; every 4 weeks for the first 6 months from the initiation of treatment, then every 8 weeks for the next 6 months, and every 12 weeks thereafter until end of study. Least-squares mean changes from baseline were estimated using a mixed-effects model by including treatment, time, and treatment-by-time interaction, and stratification factors as fixed effects. Time to first symptom improvement was assessed by Kaplan-Meier analysis. Results In mixed-effects model analysis, idelalisib + bendamustine/rituximab treatment led to clinically meaningful improvements from baseline in leukemia-associated symptoms. Moreover, per Kaplan-Meier analysis, the proportion of patients with symptom improvement was higher and time to improvement was shorter among patients in the idelalisib-containing arm compared with those who did not receive idelalisib. The physical and social/family FACT-Leu subscale scores, along with the self-rated health assessed by EQ-VAS, showed improvement with idelalisib over placebo, but the difference did not reach statistical significance. The functional and emotional FACT-Leu subscale scores remained similar to placebo. Conclusions Addition of idelalisib to bendamustine/rituximab, apart from improving PFS and OS, had a neutral to beneficial impact on HRQL in patients with R/R CLL, particularly by reducing leukemia-specific disease symptoms. Trial registration Clinicaltrials.gov NCT01569295. Registered April 3, 2012.
- Published
- 2019
4. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- Author
-
Thomas M. Habermann, Chih Jian Lih, Ranjana H. Advani, Davina Moussa, Andre Goy, Paul M. Barr, Rebecca Elstrom, Nathan Fowler, Fong Clow, Betty Y. Chang, Maria Fardis, Darrin M. Beaupre, Brian Munneke, John F. Gerecitano, Ryan M. Young, Wyndham H. Wilson, Louis M. Staudt, Roland Schmitz, Stefania Pittaluga, Vaishalee P. Kenkre, Yandan Yang, P. Mickey Williams, George E. Wright, Andrei R. Shustov, Julie M. Vose, Jacqueline C. Barrientos, Jesse McGreivy, Sven de Vos, Arthur L. Shaffer, and Kristie A. Blum
- Subjects
Adult ,Male ,Molecular Sequence Data ,B-cell receptor ,Receptors, Antigen, B-Cell ,Biology ,Article ,General Biochemistry, Genetics and Molecular Biology ,chemistry.chemical_compound ,Piperidines ,hemic and lymphatic diseases ,medicine ,Humans ,Protein Kinase Inhibitors ,Aged ,Base Sequence ,Adenine ,breakpoint cluster region ,Germinal center ,General Medicine ,Middle Aged ,CD79B ,medicine.disease ,Lymphoma ,Pyrimidines ,chemistry ,Ibrutinib ,Mutation ,Myeloid Differentiation Factor 88 ,Immunology ,Cancer research ,Pyrazoles ,Female ,Lymphoma, Large B-Cell, Diffuse ,Diffuse large B-cell lymphoma ,CD79 Antigens ,Signal Transduction - Abstract
The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like (ABC) and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling(1). The ABC subtype has a ∼40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies(2). We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling. In a phase 1/2 clinical trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106). ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), especially those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways. However, the highest number of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms. These results support the selective development of ibrutinib for the treatment of ABC DLBCL.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.